Background: Progranulin (PGRN) is a fundamental neurotrophic factor, and is also involved in inflammation and wound repair. PGRN may have pro- or anti-inflammatory properties, depending upon proteolysis of the anti-inflammatory parent PGRN protein and the generation of pro-inflammatory granulin peptides.
Objectives: Our objectives were as follows: (1) to evaluate the presence and distribution of PGRN in multiple sclerosis (MS) brain tissue, correlating it with demyelination and inflammation; (2) to evaluate cerebrospinal fluid (CSF) PGRN concentrations in patients with MS and controls, in relationship to the clinical features of the disease.
Methods: Our study involved the following: (1) neuropathological study of PGRN on post-mortem tissue of 19 MS and six control brains; (2) evaluation of PGRN CSF concentration in 40 MS patients, 15 non-inflammatory controls and five inflammatory controls (viral encephalitis).
Results: In active demyelinating lesions, PGRN was expressed on macrophages/microglia. In the normal-appearing white matter (NAWM), expression of PGRN was observed on activated microglia. PGRN was expressed by neurons and microglia in cortical lesions and in normal-appearing cortex. No expression of PGRN was observed in controls, except on neurons. PGRN CSF concentrations were significantly higher in patients with relapsing–remitting MS during relapses and in progressive MS patients, compared with relapsing–remitting MS patients during remissions and with non-inflammatory controls.
Conclusions: PGRN is strongly expressed in MS brains, by macrophages/microglia in active lesions, and by activated microglia in the NAWM; PGRN CSF concentrations in MS are correspondingly increased in conditions of enhanced macrophage/microglia activation, such as during relapses and in progressive MS.
KutzelniggALucchinettiCFStadelmannCBrückWRauschkaHBergmannM. Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain2005; 128: 2705–2712.
AhmedZMackenzieIRHuttonMLDicksonDW. Progranulin in frontotemporal lobar degeneration and neuroinflammation. J Neuroinflammation2007; 4: 7–7.
4.
EriksenJLMackenzieIR. Progranulin: normal function and role in neurodegeneration. J Neurochem2008; 104: 287–297.
5.
Van DammePVan HoeckeALambrechtsDVanackerPBogaertEvan SwietenJ. Progranulin functions as a neurotrophic factor to regulate neurite outgrowth and enhance neuronal survival. J Cell Biol2008; 181: 37–41.
6.
BakerMMackenzieIRPickering-BrownSMGassJRademakersRLindholmC. Mutations in progranulin cause tau-negative frontotemporal dementia linked to chromosome 17. Nature2006; 442: 916–919.
HeZOngCHHalperJBatemanA. Progranulin is a mediator of the wound response. Nat Med2003; 9: 225–229.
9.
ZhuJNathanCJinWSimDAshcroftGSWahlSM. Conversion of proepithelin to epithelins: roles of SLPI and elastase in host defense and wound repair. Cell2002; 111: 867–878.
10.
BöLMörkSKongPANylandHPardoCATrappBD. Detection of MHC class II-antigens on macrophages and microglia, but not on astrocytes and endothelia in active multiple sclerosis lesions. J Neuroimmunol1994; 51: 135–146.
11.
TrappBDPetersonJRansohoffRMRudickRMörkSBöL. Axonal transection in the lesions of multiple sclerosis. N Engl J Med1998; 338: 278–285.
12.
Van der ValkPDe GrootCJA. Staging of multiple sclerosis (MS) lesions: pathology of the time frame of MS. Neuropathol Appl Neurobiol2000; 26: 2–10.
13.
McDonaldWICompstonAEdanGGoodkinDHartungHPLublinFD. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol2001; 50: 121–127.
14.
LublinFDReingoldSC. Defining the clinical course of multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology1996; 46: 907–911.
15.
TeunissenCEPetzoldABennettJLBervenFSBrundinLComabellaM. A consensus protocol for the standardization of cerebrospinal fluid collection and biobanking. Neurology2009; 73: 1914–1922.
16.
MackenzieIRBakerMPickering-BrownSHsiungGYLindholmCDwoshE. The neuropathology of frontotemporal lobar degeneration caused by mutations in the progranulin gene. Brain2006; 129: 3081–3090.
17.
MukherjeeOPastorPCairnsNJChakravertySKauweJSShearsS. HDDD2 is a familial frontotemporal lobar degeneration with ubiquitin-positive, tau-negative inclusions caused by a missense mutation in the signal peptide of progranulin. Ann Neurol2006; 60: 314–322.
18.
BakerCAManuelidisL. Unique inflammatory RNA profiles of microglia in Creutzfeldt-Jakob disease. Proc Natl Acad Sci U S A2003; 100: 675–679.
19.
NaphadeSBKigerlKAJakemanLBKostykSKPopovichPGKuretJ. Progranulin expression is upregulated after spinal contusion in mice. Acta Neuropathol2010; 119: 123–133.
20.
YinFBanerjeeRThomasBZhouPQianLJiaT. Exaggerated inflammation, impaired host defense, and neuropathology in progranulin-deficient mice. J Exp Med2010; 207: 117–128, S1–S4.
21.
MagliozziRHowellOVoraASerafiniBNicholasRPuopoloM. Meningeal B-cell follicles in secondary progressive multiple sclerosis associate with early onset of disease and severe cortical pathology. Brain2007; 130: 1089–1104.
22.
De RizMGalimbertiDFenoglioCPiccioLMScalabriniDVenturelliE. Cerebrospinal fluid progranulin levels in patients with different multiple sclerosis subtypes. Neurosci Lett2010; 469: 234–236.
23.
HohlfeldR. Neurotrophic cross-talk between the nervous and immune systems: relevance for repair strategies in multiple sclerosis?. J Neurol Sci2008; 265: 93–96.
24.
ZeisTGraumannUReynoldsRSchaeren-WiemersN. Normal-appearing white matter in multiple sclerosis is in a subtle balance between inflammation and neuroprotection. Brain2008; 131: 288–303.
